Judge Mulls BioXcel's Duty To Tell Investors Of FDA Troubles
By Brian Steele · June 24, 2024, 9:39 PM EDT
A Connecticut federal judge wondered Monday if executives at the artificial intelligence-driven drugmaker BioXcel Therapeutics Inc. had an opportunity to correct problems that government regulators identified with a key clinical trial...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login